Functional expression of TRAIL by lymphoid and myeloid tumour cells

被引：33

作者：

Zhao, SR

Asgary, Z

Wang, Y

Goodwin, R

Andreeff, M

Younes, A

机构：

[1] Univ Texas, MD Anderson Canc Ctr, Dept Mol Hematol & Therapy, Houston, TX 77030 USA

[2] Univ Texas, MD Anderson Canc Ctr, Dept Lymphoma, Houston, TX 77030 USA

[3] Immunex Corp, Seattle, WA USA

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 1999年 / 106卷 / 03期

关键词：

apoptosis; leukaemia; lymphoma; immunosurveillance; Fas;

D O I：

10.1046/j.1365-2141.1999.01630.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

TRAIL is a potent death protein that favours the killing of various types of cancer cells to normal cells, but under the right conditions TRAIL can also kill activated human T cells. TRAIL mRNA is widely expressed by normal cells but its expression by primary tumour cells is not known. In this study, primary tumour cells of haemopoietic origin constitutively expressed TRAIL mRNA and protein and were capable of inducing the apoptosis of target Jurkat cells in a dose-dependent manner. This killing effect was reversed by anti-TRAIL antibody. The functional expression of TRAIL by lymphoid and myeloid malignant cells raises the possibility of its involvement in tumour cell evasion of immunosurveillance, and could be related to spontaneous tumour cell death and necrosis.

引用

收藏

页码：827 / 832

页数：6

相关论文

共 34 条

[1] Missense mutations in the Fas gene resulting in autoimmune lymphoproliferative syndrome: A molecular and immunological analysis [J].

Bettinardi, A ;

Brugnoni, D ;

QuirosRoldan, E ;

Malagoli, A ;

LaGrutta, S ;

Correra, A ;

Notarangelo, LD .

BLOOD, 1997, 89 (03) :902-909

[2] Coexpression of CD40 and CD40 ligand in B-cell lymphoma cells [J].

Clodi, K ;

Asgary, Z ;

Zhao, SR ;

Kliche, KO ;

Cabanillas, F ;

Andreeff, M ;

Youns, A .

BRITISH JOURNAL OF HAEMATOLOGY, 1998, 103 (01) :270-275

[3] The novel receptor TRAIL-R4 induces NF-κB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain [J].

Degli-Esposti, MA ;

Dougall, WC ;

Smolak, PJ ;

Waugh, JY ;

Smith, CA ;

Goodwin, RG .

IMMUNITY, 1997, 7 (06) :813-820

[4] Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family [J].

DegliEsposti, MA ;

Smolak, PJ ;

Walczak, H ;

Waugh, J ;

Huang, CP ;

DuBose, RF ;

Goodwin, RG ;

Smith, CA .

JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 186 (07) :1165-1170

[5] Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity [J].

Drappa, J ;

Vaishnaw, AK ;

Sullivan, KE ;

Chu, JL ;

Elkon, KB .

NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (22) :1643-1649

[6] Cell death: TRAIL and its receptors [J].

Golstein, P .

CURRENT BIOLOGY, 1997, 7 (12) :R750-R753

[7] TRAIL: a molecule with multiple receptors and control mechanisms [J].

Griffith, TS ;

Lynch, DH .

CURRENT OPINION IN IMMUNOLOGY, 1998, 10 (05) :559-563

[8] Cancer research - How TRAIL kills cancer cells, but not normal cells [J].

Gura, T .

SCIENCE, 1997, 277 (5327) :768-768

[9] Melanoma cell expression of Fas(Apo-1/CD95) ligand: Implications for tumor immune escape [J].

Hahne, M ;

Rimoldi, D ;

Schroter, M ;

Romero, P ;

Schreier, M ;

French, LE ;

Schneider, P ;

Bornand, T ;

Fontana, A ;

Lienard, D ;

Cerottini, JC ;

Tschopp, J .

SCIENCE, 1996, 274 (5291) :1363-1366

[10]

Jeremias I, 1998, EUR J IMMUNOL, V28, P143, DOI 10.1002/(SICI)1521-4141(199801)28:01<143::AID-IMMU143>3.0.CO

← 1 2 3 4 →